-
Mashup Score: 0
High prevalence of exceeding moderate drinking, binge drinking, hazardous drinking behavior
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0Survival Calculator Takes 'Holistic' Approach in Oral Cancer - 2 year(s) ago
But experts urge caution with this prediction tool
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#AHNS23: A predictive calculator aims to offer patients with #oralcancer a personalized estimate of survival that takes into consideration the effects of co-existing conditions. #OncTwitter https://t.co/qSVcZnjjbD
-
-
Mashup Score: 0Adaptive RT Fails to Relieve Dry Mouth in Head and Neck Cancer - 2 year(s) ago
‘Expensive and intensive’ process does not translate into clinical benefit, researchers conclude
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Use of weekly adaptive #radiotherapy failed to decrease #xerostomia (dry mouth) in #oropharyngeal cancer patients when compared with standard intensity-modulated RT (IMRT), the phase III ARTIX trial found. #OncTwitter #MedTwitter https://t.co/TlEFvhyiRb
-
-
Mashup Score: 0
News, features, and commentary about cancer-related issues
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Hey #OncTwitter, it's time for #OncoBreak! 🧵 https://t.co/FqddEL3V2X
-
-
Mashup Score: 0New Ovarian Cancer Drug Extends Survival in Resistant Disease - 2 year(s) ago
‘Practice changing’ findings for tough-to-treat patient population
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
A novel drug, an antibody-microtubule inhibitor conjugate, showed improved survival in selected patients with advanced platinum-resistant #ovariancancer compared to standard #chemotherapy in a phase III trial. @ASCO #ASCO #ASCO23 #OncoTwitter https://t.co/uglMRUdJsP
-
-
Mashup Score: 0
Survival 13 months better with surgery, but ‘curiosities’ in neoadjuvant arm muddy the results
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Neoadjuvant #chemotherapy failed to match upfront surgery for survival in resectable #pancreaticcancer, a small randomized trial showed. @ASCO #ASCO #ASCO23 #OncoTwitter https://t.co/4kiYHUDyvY
-
-
Mashup Score: 0Survival Boost With Oncolytic Virus Combo in Glioblastoma Subset - 2 year(s) ago
However, small trial failed to meet overall response endpoint in patients with recurrent disease
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
The combination of oncolytic DNX-2401 virotherapy with #Keytruda failed to meet a phase I/II study's primary endpoint of #ORR in patients with recurrent #glioblastoma, but did demonstrate a "notable survival benefit" in select patients. #OncoTwitter https://t.co/bcCHTQOaCK
-
-
Mashup Score: 0
Median OS improved from 15 months to nearly 32 months with quizartinib
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
"Quizartinib provides a new, effective, and generally well-tolerated treatment option for adult patients with FLT3-ITD-positive newly diagnosed AML," said Harry P. Erba, MD, of @DukeCancer. #Lukemia #Cancer #OncoTwitter https://t.co/aYawsOGReu
-
-
Mashup Score: 0
Device allows delivery of more potent chemotherapies to patients with glioblastomas
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
"Results from this phase I clinical trial suggest that #ultrasound treatments can enhance #chemotherapeutic delivery of different agents by up to six times in patients with #braintumors," -- Antonios N. Pouliopoulos of @KingsCollegeLon #OncoTwitter https://t.co/1HV6gogQoS
-
-
Mashup Score: 0Antibody-Drug Conjugate Gets FDA Thumbs Up for Untreated DLBCL - 2 year(s) ago
Adding polatuzumab vedotin to a modified version of R-CHOP significantly improved PFS
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
The FDA approved the antibody-drug conjugate (#ADC) polatuzumab vedotin (#Polivy) plus standard therapy for certain types of untreated diffuse large B-cell lymphoma (#DLBCL), according to a statement from @genentech. #FDAapproved #OncoTwitter #MedTwitter https://t.co/zG8S2hXQGD
-
"This cross-sectional study of a diverse U.S. cohort suggests that #alcohol consumption and risky drinking were common among #cancer survivors, even among individuals receiving treatment," --Yin Cao, ScD, MPH, of @WUSTL. #OncTwitter #MedTwitter https://t.co/gh7wnJaj9J